What is new in the treatment of melanoma skin cancer? Read our melanoma skin cancer blog and learn more about the latest advancements in the treatment of melanoma skin cancer.

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 19-Nov-2018

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

PD-1 mAB cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

On September 28, 2018, the FDA approved programmed death 1 (PD-1) immune-checkpoint inhibitor cemiplimab-rwlc (Libtayo®, Regeneron) for use in patients with metastatic cutaneous squamous cell carcinoma (CSCC) and patients with locally advanced CSCC unamenable for curative surgery or curative radiation.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Anti-PD1 with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Programmed death 1 (PD-1) inhibition with the novel human anti-PD1 monoclonal antibody cemiplimab (REGN2810, Regeneron and Sanofi) in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma (CSCC) resulted in a response in approximately half of the patients.

Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma

The FDA granted regular approval to dabrafenib (Tafinlar®, Novartis) and trametinib (Mekinist®, Novartis) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. 

PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

Exclusive subscriber download.

ESMO 2016 ipilimumab data medipaper medical communications

ESMO16 Ipilimumab data – Download the PPT

Exclusive subscriber download.

ESMO 2016 pembrolizumab data medipaper medical communications

ESMO16 Pembrolizumab data – Download the PPT

Exclusive subscriber download.

ESMO 2016 nivolumab data medipaper medical communications

ESMO16 Nivolumab data – Download the PPT

Exclusive subscriber download.

ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

ASCO16 Avelumab, Durvalumab, and Tremelimumab

Exclusive subscriber download.

ASCO2016 ipilimumab data - MediPaper Medical Communications

ASCO16 Ipilimumab (Yervoy©) Data

Exclusive subscriber download.

asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

Exclusive subscriber download.

asco 2016 pembrolizumab medipaper medical communications

ASCO16 Pembrolizumab (Keytruda©) Data

Exclusive subscriber download.